title: Molecular Mechanisms of Antisense Oligonucleotides.
abstract: In 1987, when I became interested in the notion of antisense technology, I returned to my roots in RNA biochemistry and began work to understand how oligonucleotides behave in biological systems. Since 1989, my research has focused primarily on this topic, although I have been involved in most areas of research in antisense technology. I believe that the art of excellent science is to frame large important questions that are perhaps not immediately answerable with existing knowledge and methods, and then conceive a long-term (multiyear) research strategy that begins by answering the most pressing answerable questions on the path to the long-term goals. Then, a step-by-step research pathway that will address the strategic questions posed must be implemented, adjusting the plan as new things are learned. This is the approach we have taken at Ionis. Obviously, to create antisense technology, we have had to address a wide array of strategic questions, for example, the medicinal chemistry of oligonucleotides, manufacturing and analytical methods, pharmacokinetics and toxicology, as well as questions about the molecular pharmacology of antisense oligonucleotides (ASOs). Each of these endeavors has consumed nearly three decades of scientific effort, is still very much a work-in-progress, and has resulted in hundreds of publications. As a recipient of the Lifetime Achievement Award 2016 granted by the Oligonucleotide Therapeutic Society, in this note, my goal is to summarize the contributions of my group to the efforts to understand the molecular mechanisms of ASOs.
authors.affiliation: Department of Core Antisense Research, Ionis Pharmaceuticals, Inc. , Carlsbad, California.
authors.forename: Stanley T
authors.initials: ST
authors.lastname: Crooke
mesh_terms: D001692:Biological Transport; D002462:Cell Membrane / Q000378:metabolism; D005057:Eukaryotic Cells / Q000166:cytology / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000235:genetics* / Q000378:metabolism; D009693:Nucleic Acid Hybridization; D016376:Oligonucleotides, Antisense / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D011951:Receptors, Complement / Q000235:genetics* / Q000378:metabolism; D016914:Ribonuclease H / Q000235:genetics* / Q000378:metabolism
chemical_list: D008562:Membrane Glycoproteins; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D011951:Receptors, Complement; C032402:complement 1q receptor; D016914:Ribonuclease H; C078856:ribonuclease HI
keywords: DNA; RNA; RNase H; antisense; mechanisms; oligonucleotide